| P/E (FY) | — | Sales (TTM) | $116.3M |
| Earnings (TTM) | -$11.1M | ROE | −7.32% |
| Net Margin | −9.64% | ROIC | −9.47% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −0.30% |
Anika Therapeutics, Inc. is a joint preservation company focused on early intervention orthopedics in the United States, Europe, and internationally. It offers osteoarthritis pain management products such as Monovisc, Orthovisc, and Cingal, along with regenerative solutions including HA-based scaffolds, Hyalofast for cartilage regeneration, and Tactoset injectable bone substitute for treating insufficiency fractures and augmenting hardware fixation.
| Market Cap | $201.6M | Trading Days | 5292 |
| 52W High | 16.49 |
| 52W Low | 7.87 |
| % Off High | −8.13% |
| YTD | 57.65% | 1Y | 33.72% |
| 3Y | −36.95% | 5Y | −63.68% |
| 10Y | −69.22% | Since incept. (ann.) | 1.43% |
US 62% · Europe 20% · Other Location 18%
| Ann. Volatility (1Y) | 56.12% | Ann. Volatility (3Y) | 48.44% |
| Sharpe (1Y) | 0.82 | Sharpe (3Y) | −0.08 |
| Max Drawdown (1Y) | −28.51% | Max Drawdown (3Y) | −71.83% |
| Beta (3Y, vs SPY) | 0.01 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| INFU | InfuSystem Holdings, Inc | $200.2M | 32.0 |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| LUCD | Lucid Diagnostics Inc. | $185.7M | — |
| KRMD | KORU Medical Systems, Inc. | $184.2M | — |
| PDEX | PRO DEX INC | $179.9M | 21.1 |
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| OBIO | Orchestra BioMed Holdings, Inc. | $231.1M | — |
| APYX | Apyx Medical Corp | $161.6M | — |
| PROF | Profound Medical Corp. | $263.4M | 5.1 |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| ORASURE TECHNOLOGIES INC |
| $276.8M |
| — |
